Designing the future of medicine
We use AI to design peptides with custom targeting properties for therapeutics
Designed Biologics is dedicated to the development of small peptides (30 to 75 amino acids) with “designed” targeting properties. This is done through the principles of alternative protein-protein interactions that mediate a subset of natural protein interactions.
Combining molecular interaction dynamics with AI technology and high-performance computing, Designed Biologics thrives in architecting alternative peptides that can bind and deactivate protein targets. These AI driven peptides can be used as therapeutics and diagnostic tools, as well as for research purposes.
Our computational platform offers the first-class solution for designing nano IgG-like specific antibodies (30-75 amino acids) for the tackling protein targets. The speed and accuracy associated with our platform provides an ideal solution to focus multiple sites of multiple protein targets.
The designed biologics are selected against non-target proteins reducing the possibility of side effects. The small size of our designed biologics (30-75 amino acids) makes them ideal therapeutics for reaching hidden targets. Using the alternative mechanism for protein-protein interaction, our platform combines the biochemical and biophysical properties of proteins with AI and high-performance computing to engineer peptide therapeutics that interact with difficult pharmaceutically valuable targets.
Designed Biologics is fully committed to different commercial and academic collaborations. We also have a series of ongoing internal R&D projects:
Design and development of peptides against certain KRAS mutants.
Development of peptides that interfere with GP1BA-VWF interaction.
Design and development of peptides against SARS-COV-2 surface S protein.
Design and development of peptides against Psk1.
Design and development of peptides against Salmonella flagellum proteins.
A computational approach to rapidly design peptides that detect SARS-CoV-2 surface protein S. Hajikarimlou et al 2022 NAR Genom Bioinf
In Silico Engineering of Synthetic Binding Proteins from Random Amino Acid Sequences. Burnside et al 2019 iScience
Efficient prediction of human protein-protein interactions at a global scale. Schoenrock et l 2014 BMC Bioinformatics
Short Co-occurring Polypeptide Regions Can Predict Global Protein Interaction Maps. Pitre et al 2012 Scientific Report
Design Biologics is proud to announce that starting January 2024, Designed Biologics is planning an ambitious project to design and develop a pair of interacting peptides for 1,000 human essential proteins.
This is with the ultimate goal of designing a pair of peptides for the entire human proteome.